Emergent BioSolutions | EBS - Market Capitalization


Emergent BioSolutions reported $386.8M in Market Capitalization this August of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.53B 199M Aug/2026
Akebia Therapeutics USD 427M 297M Dec/2025
ALKERMES USD 7.93B 806M Aug/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amarin USD 290M 51M Dec/2025
ANI Pharmaceuticals USD 1.75B 24M Mar/2026
BioMarin Pharmaceutical USD 11.41B 550M Aug/2026
Coherus Biosciences USD 172M 19M Dec/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 10.89B 857M Mar/2026
Glaxosmithkline GBP 109.29B 9.36B Mar/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 326.56B 29.46B Aug/2026
Nektar Therapeutics USD 12.98B 10.86B Aug/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pacira USD 1.25B 333M Aug/2026
Pfizer USD 144.23B 5.78B Aug/2026
Sanofi EUR 91.15B 9.12B Jun/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
United Therapeutics USD 25.19B 4.21B Mar/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024